Income Statement (TTM)
ImmunoPrecise Antibodies Ltd. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 10-31 |
2021 01-31 |
2021 04-30 |
2021 07-31 |
2021 10-31 |
2022 01-31 |
2022 04-30 |
2022 07-31 |
2022 10-31 |
2023 01-31 |
2023 04-30 |
2023 07-31 |
2023 10-31 |
2024 01-31 |
2024 04-30 |
2024 07-31 |
2024 10-31 |
2025 01-31 |
2025 04-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17 | 17 | 18 | 19 | 19 | 19 | 19 | 19 | 20 | 20 | 21 | 22 | 23 | 24 | 25 | 24 | 24 | 24 | 25 |
| Change (%) | 2.88 | 4.26 | 4.59 | -0.18 | 1.60 | 1.91 | 0.52 | 2.37 | 1.79 | 1.88 | 4.83 | 4.45 | 4.64 | 3.54 | -1.73 | -0.10 | -0.29 | 2.18 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 8 | 7 | 7 | 7 | 7 | 9 | 8 | 8 | 9 | 9 | 9 | 10 | 11 | 11 | 12 | 12 | 12 | 12 | 11 |
| Change (%) | -11.36 | -2.57 | 11.77 | -0.18 | 17.17 | -1.49 | 0.95 | 3.62 | -0.25 | 4.08 | 7.50 | 8.09 | 7.72 | 9.40 | 0.11 | -4.08 | -1.40 | -7.03 | |
| % of Revenue | 45.13 | 38.88 | 36.33 | 38.83 | 38.82 | 44.77 | 43.28 | 43.47 | 44.00 | 43.11 | 44.05 | 45.17 | 46.74 | 48.12 | 50.84 | 51.80 | 49.73 | 49.18 | 44.75 |
| Gross Operating Profit | 9 | 11 | 11 | 11 | 11 | 10 | 11 | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 14 |
| Change (%) | 14.59 | 8.61 | 0.50 | -0.17 | -8.28 | 4.66 | 0.19 | 1.42 | 3.39 | 0.22 | 2.73 | 1.46 | 1.94 | -1.90 | -3.64 | 4.18 | 0.80 | 11.09 | |
| % of Revenue | 54.87 | 61.12 | 63.67 | 61.17 | 61.18 | 55.23 | 56.72 | 56.53 | 56.00 | 56.89 | 55.95 | 54.83 | 53.26 | 51.88 | 49.16 | 48.20 | 50.27 | 50.82 | 55.25 |
| SG&A | 10 | 12 | 13 | 15 | 16 | 17 | 18 | 18 | 19 | 19 | 18 | 18 | 18 | 18 | 19 | 19 | 19 | 19 | 19 |
| Change (%) | 23.29 | 12.17 | 14.23 | 6.58 | 3.19 | 7.68 | 1.40 | 1.64 | 3.30 | -5.36 | -1.35 | 0.33 | -0.67 | 6.99 | -1.90 | 2.53 | 0.39 | -1.50 | |
| % of Revenue | 57.79 | 69.25 | 74.51 | 81.37 | 86.88 | 88.24 | 93.24 | 94.06 | 93.38 | 94.77 | 88.03 | 82.84 | 79.57 | 75.53 | 78.04 | 77.91 | 79.97 | 80.52 | 77.62 |
| R&D | 1 | 1 | 2 | 3 | 5 | 7 | 8 | 13 | 15 | 15 | 14 | 9 | 4 | 4 | 4 | 5 | 5 | 5 | 5 |
| Change (%) | -4.55 | 73.66 | 41.03 | 75.90 | 42.03 | 10.18 | 66.11 | 17.90 | -3.30 | -2.84 | -37.15 | -51.98 | -13.18 | 9.42 | 17.19 | 6.78 | 1.09 | -3.34 | |
| % of Revenue | 7.13 | 6.62 | 11.02 | 14.86 | 26.18 | 36.60 | 39.57 | 65.39 | 75.31 | 71.55 | 68.24 | 40.91 | 18.81 | 15.60 | 16.49 | 19.67 | 21.02 | 21.31 | 20.16 |
| OpEx | 21 | 22 | 25 | 28 | 31 | 34 | 36 | 42 | 45 | 46 | 46 | 41 | 37 | 37 | 39 | 39 | 39 | 39 | 37 |
| Change (%) | 6.11 | 9.99 | 14.11 | 9.73 | 11.68 | 5.12 | 16.17 | 8.34 | 1.38 | -0.59 | -11.06 | -9.81 | -0.51 | 5.62 | 0.27 | 0.49 | -0.32 | -4.86 | |
| % of Revenue | 126.05 | 130.00 | 137.14 | 149.62 | 164.47 | 180.79 | 186.49 | 215.53 | 228.08 | 227.18 | 221.67 | 188.07 | 162.39 | 154.38 | 157.48 | 160.69 | 161.64 | 161.61 | 150.47 |
| Operating Income | -4 | -5 | -7 | -9 | -12 | -15 | -17 | -22 | -26 | -26 | -25 | -19 | -14 | -13 | -14 | -15 | -15 | -15 | -12 |
| Change (%) | 18.49 | 29.07 | 39.74 | 29.69 | 27.32 | 9.10 | 34.27 | 13.50 | 1.07 | -2.53 | -24.12 | -26.00 | -8.78 | 9.43 | 3.76 | 1.46 | -0.35 | -16.29 | |
| % of Revenue | -26.05 | -30.00 | -37.14 | -49.62 | -64.47 | -80.79 | -86.49 | -115.53 | -128.08 | -127.18 | -121.67 | -88.07 | -62.39 | -54.38 | -57.48 | -60.69 | -61.64 | -61.61 | -50.47 |
| Interest Expense | -1 | -1 | -1 | -1 | -1 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -0 | -0 | -0 | |
| Change (%) | -2.06 | -22.38 | -10.45 | -6.97 | -41.01 | -73.02 | -47.73 | 30.43 | 36.67 | -75.61 | -100.00 | -∞ | 1,021.05 | -38.97 | 136.92 | -4.87 | |||
| % of Revenue | -5.05 | -4.81 | -3.58 | -3.06 | -2.86 | -1.66 | -0.44 | -0.22 | -0.11 | -0.15 | -0.19 | -0.04 | 0.00 | -0.08 | -0.88 | -0.54 | -1.28 | -1.19 | |
| Net Income | -3 | -3 | -7 | -10 | -15 | -17 | -17 | -23 | -25 | -26 | -27 | -21 | -16 | -14 | -26 | -28 | -28 | -47 | -30 |
| Change (%) | 25.86 | 125.68 | 36.53 | 45.35 | 17.38 | -2.28 | 36.81 | 10.24 | 3.46 | 1.86 | -22.46 | -23.99 | -12.91 | 91.54 | 6.30 | 0.51 | 67.53 | -35.32 | |
| % of Revenue | -15.48 | -18.93 | -40.98 | -53.49 | -77.88 | -89.98 | -86.29 | -117.44 | -126.47 | -128.56 | -128.53 | -95.07 | -69.18 | -57.58 | -106.51 | -115.22 | -115.93 | -194.79 | -123.30 |
Source: Capital IQ
